Literature DB >> 15059887

Kallikrein 4 is a predominantly nuclear protein and is overexpressed in prostate cancer.

Zhijun Xi1, Tove Irene Klokk, Kemal Korkmaz, Piotr Kurys, Cem Elbi, Bjørn Risberg, Håvard Danielsen, Massimo Loda, Fahri Saatcioglu.   

Abstract

Kallikreins (KLKs) are highly conserved serine proteases that play key roles in a variety of physiological and pathological processes. KLKs are secreted proteins that have extracellular substrates and function. For example, prostate-specific antigen (or KLK3) is a secreted protein that is widely used as a diagnostic marker for prostate cancer. KLK4 is a recently identified member of the kallikrein family that is regulated by androgens and is highly specific to prostate for expression. Here, we show that the gene product of KLK4, hK4, is the first member of the KLK family that is intracellularly localized. We provide strong evidence that the previously assigned first exon that was predicted to code for a signal peptide that would target hK4 for secretion is not part of the physiologically relevant form of KLK4 mRNA. In addition to detailed mapping of the KLK4 mRNA 5' end by RT-PCR, this conclusion is supported by predominantly nuclear localization of the hK4 protein in the cell, documented by both immunofluorescence and cell fractionation experiments. Furthermore, in addition to androgens, hK4 expression is regulated by estrogen and progesterone in prostate cancer cells. Finally, in situ hybridization on normal and hyperplastic prostate samples in tissue microarrays indicate that KLK4 is predominantly expressed in the basal cells of the normal prostate gland and overexpressed in prostate cancer. These data suggest that KLK4 has a unique structure and function compared with other members of the KLK family and may have a role in the biology and characterization of prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15059887     DOI: 10.1158/0008-5472.can-03-2025

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  25 in total

1.  PSA regulates androgen receptor expression in prostate cancer cells.

Authors:  Parmita Saxena; Marco Trerotola; Tao Wang; Jing Li; Aejaz Sayeed; Jennifer Vanoudenhove; Dave S Adams; Thomas J Fitzgerald; Dario C Altieri; Lucia R Languino
Journal:  Prostate       Date:  2011-09-28       Impact factor: 4.104

Review 2.  Current Transport Systems and Clinical Applications for Small Interfering RNA (siRNA) Drugs.

Authors:  Fang Liu; Chunfang Wang; Yuantao Gao; Xiao Li; Feng Tian; Yongtao Zhang; Mingyang Fu; Pengfei Li; Yali Wang; Fei Wang
Journal:  Mol Diagn Ther       Date:  2018-10       Impact factor: 4.074

3.  Virtual Screening and X-ray Crystallography for Human Kallikrein 6 Inhibitors with an Amidinothiophene P1 Group.

Authors:  Guyan Liang; Xin Chen; Suzanne Aldous; Su-Fen Pu; Shujaath Mehdi; Elaine Powers; Andrew Giovanni; Sathapana Kongsamut; Tianhui Xia; Ying Zhang; Rachel Wang; Zhongli Gao; Gregory Merriman; Larry R McLean; Isabelle Morize
Journal:  ACS Med Chem Lett       Date:  2012-01-11       Impact factor: 4.345

4.  Molecular circuit involving KLK4 integrates androgen and mTOR signaling in prostate cancer.

Authors:  Yang Jin; Su Qu; Martina Tesikova; Ling Wang; Alexandr Kristian; Gunhild M Mælandsmo; Haiying Kong; Tianzhou Zhang; Carmen Jerónimo; Manuel R Teixeira; Erkan Yuca; Ibrahim Tekedereli; Kivanc Gorgulu; Neslihan Alpay; Anil K Sood; Gabriel Lopez-Berestein; Håvard E Danielsen; Bulent Ozpolat; Fahri Saatcioglu
Journal:  Proc Natl Acad Sci U S A       Date:  2013-06-24       Impact factor: 11.205

5.  Clinical significance of kallikrein-related peptidase-4 in oral cancer.

Authors:  Petros Papagerakis; Giuseppe Pannone; L I Zheng; Maria Athanassiou-Papaefthymiou; Yashuo Yamakoshi; Howard Stan McGuff; Omar Shkeir; Konstantinos Ghirtis; Silvana Papagerakis
Journal:  Anticancer Res       Date:  2015-04       Impact factor: 2.480

6.  Three dysregulated miRNAs control kallikrein 10 expression and cell proliferation in ovarian cancer.

Authors:  N M A White; T-F F Chow; S Mejia-Guerrero; M Diamandis; Y Rofael; H Faragalla; M Mankaruous; M Gabril; A Girgis; G M Yousef
Journal:  Br J Cancer       Date:  2010-03-30       Impact factor: 7.640

Review 7.  Emerging PSA-based tests to improve screening.

Authors:  Richard J Bryant; Hans Lilja
Journal:  Urol Clin North Am       Date:  2014-02-26       Impact factor: 2.241

8.  Association of transcript levels of 10 established or candidate-biomarker gene targets with cancerous versus non-cancerous prostate tissue from radical prostatectomy specimens.

Authors:  Riina-Minna Väänänen; Hans Lilja; Angel Cronin; Leni Kauko; Maria Rissanen; Otto Kauko; Henna Kekki; Siina Vidbäck; Martti Nurmi; Kalle Alanen; Kim Pettersson
Journal:  Clin Biochem       Date:  2013-02-04       Impact factor: 3.281

9.  Small integrin-binding proteins as serum markers for prostate cancer detection.

Authors:  Alka Jain; Dianalee A McKnight; Larry W Fisher; Elizabeth B Humphreys; Leslie A Mangold; Alan W Partin; Neal S Fedarko
Journal:  Clin Cancer Res       Date:  2009-08-11       Impact factor: 12.531

Review 10.  Delivery strategies and potential targets for siRNA in major cancer types.

Authors:  So Jin Lee; Min Ju Kim; Ick Chan Kwon; Thomas M Roberts
Journal:  Adv Drug Deliv Rev       Date:  2016-05-31       Impact factor: 15.470

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.